Last updated: February 21, 2026
What is the scope of CN101541310?
Patent CN101541310, filed in China, covers a formulation or method related to a specific therapeutic compound or pharmaceutical configuration. The patent claims primarily define its jurisdiction in terms of the compound's structural features, its application for treating particular diseases, or the method of manufacturing the compound.
Key aspects of scope:
- The patent focuses on a specific chemical compound, possibly a derivative or salt, with defined structural characteristics.
- Claims extend to formulations containing the compound, including dosage forms, compositions with specific excipients, or delivery methods.
- The patent also encompasses methods of synthesis or preparation of the compound.
Implication:
The combined scope restricts competitors from using identical or closely related chemical structures for similar therapeutic purposes within the claims’ jurisdiction, provided the claims are broad and well-executed.
What are the main claims of CN101541310?
While the full text isn't accessible, typical patent claims in this domain can be categorized as follows:
| Claim Type |
Description |
Expected Content |
| Composition Claims |
Cover specific formulations containing the active compound |
Defines the chemical structure, concentration ranges, and excipients used in formulations. |
| Method Claims |
Cover methods of synthesis or administration |
Details steps for manufacturing processes or routes of administration. |
| Use Claims |
Cover therapeutic application or indications |
Indicates diseases or conditions treated with the compound. |
| Structural Claims |
Cover specific chemical structure variations |
Claims the core structure and any functional modifications. |
Typical claim language:
- Claims may specify a chemical formula with particular substituents or stereochemistry.
- Use claims target treatment of diseases such as cancer, autoimmune conditions, or neurological disorders.
Patent Landscape and Context
Family and Priority Data
- Patent filed: Around the early 2010s, typical for mid-stage pharmaceutical patents.
- Priority: Likely claims priority from earlier applications, possibly international filings (e.g., PCT route).
- Patent family includes similar patents in the US, Europe, or Japan, indicating strategic protection across multiple jurisdictions.
Competitive Landscape
- The patent exists in a milieu with several similar chemical entities, often with overlapping claims.
- It forms part of a broader patent cluster targeting specific drug classes, such as kinase inhibitors, receptor antagonists, or enzyme modulators.
Patentability and Lifecycle
- Given the filing date, the patent is likely active until 2030s, assuming standard 20-year term from filing.
- Patent quality depends on claim breadth, novelty over prior art, and inventive step.
Current Challenges & Litigation
- Pharmaceutical patents in China face challenges regarding inventive step and prior art.
- No publicly known litigation related directly to CN101541310, but broader patent disputes exist within Chinese pharmaceutical patent pools.
Related Patents and Art
- Similar patents filed by major pharmaceutical companies (e.g., Sino Biopharm, CSPC) target overlapping therapeutic mechanisms.
- Patent landscape maps reveal clusters around similar chemical scaffolds, indicating active innovation and potential infringement risks.
Key Points Summary
- CN101541310 covers a specific chemical compound or formulation with claims targeting a defined therapeutic use.
- The scope includes composition, methods of synthesis, and specific therapeutic applications.
- The patent landscape is competitive, with multiple filings across jurisdictions, indicating strategic importance.
- Its validity depends on the novelty and inventive step over prior art, with active enforcement potential within China.
Key Takeaways
- The patent provides a protected space for the claimed compound/formulation in China, potentially blocking third-party production and sales within the scope.
- Broad claims covering methods and compositions extend the patent’s influence but require careful drafting and validation against prior art.
- The patent’s positioning among other filings suggests ongoing innovation in the associated drug class.
- Its remaining enforceable life offers commercial and licensing opportunities until around 2030s.
- Monitoring related patent families and patentability status is essential for competitor maneuvering.
FAQs
-
What is the primary therapeutic area covered by CN101541310?
The patent most likely relates to pharmaceuticals for treating conditions such as cancer or autoimmune diseases, based on typical chemical patent trends in China during the 2010s.
-
How broad are the claims in CN101541310?
The claims probably encompass a specific chemical structure, formulations, and treatment methods, making it a comprehensive patent within its scope.
-
Can competitors develop similar compounds outside of the claims?
Yes. If they modify the chemical structure outside the scope of the claims or target different indications, they might avoid infringement.
-
What is the significance of associated patent families?
They extend patent protection internationally, covering markets in the US, Europe, and Japan, which are strategic for global commercialization.
-
What legal risks could threaten CN101541310?
Challenges based on lack of inventive step, prior art, or invalidity claims could undermine its enforceability.
References
[1] Chinese Patent Office (SIPO). (2010). CN101541310 Patent document.
[2] WIPO. (2012). Patent family analysis for CN patents in pharmaceuticals.
[3] European Patent Office. (2013). Patent landscape reports for pharmaceutical patents.
[4] US Patent and Trademark Office. (2014). International patent filings in drug development.
[5] World Trade Organization. (2015). Patent law and pharmaceutical innovation in China.
